Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

← The archive

archived as published

Friday, 30 October · prices through NSE close

Paras Healthcare shares list at 4% premium, and 5 more corroborated developments

1

Paras Healthcare shares list at 4% premium

Paras Healthcare's shares listed on stock exchanges on October 28, 2026, at approximately 4% premium to the IPO issue price of Rs 693 per share. The Rs 1,450 crore IPO opened for subscription on October 21 and closed on October 23, having received 34% subscription by October 22.

2

Bajaj Auto reports 35% profit growth in Q2 FY27

Bajaj Auto's standalone net profit rose 35.25% year-on-year to Rs 3,353.76 crore in Q2 FY27, beating Bloomberg estimates of Rs 3,152 crore. The company reported its first-ever quarter with revenue above Rs 20,000 crore, with consolidated net profit attributable to shareholders rising 61.9% to Rs 3,436.10 crore and consolidated revenue increasing 59.7% to Rs 25,125.56 crore, supported by pricing, a richer sales mix and currency gains.

3

Maruti Suzuki net profit falls 26 percent in Q2

Maruti Suzuki reported a 26% year-on-year decline in consolidated net profit to Rs 2,466 crore for the July-September quarter of FY27. Revenue rose 26% to Rs 53,355.5 crore, driven by record quarterly vehicle sales of 696,654 units, though higher input costs from the West-Asia conflict pressured profitability.

4

Reliance Jio adds 2.71 million mobile subscribers in September

Reliance Jio added 2.71 million subscribers during September, bringing its mobile subscriber base to 511.14 million. Bharti Airtel added 2.69 million subscribers, reaching a total of 494.29 million.

5

Kotak Mahindra Bank reports 26% profit growth in Q2

6

Ambuja Cements reports sharp profit decline in Q2

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.